scPharmaceuticals/SCPH
$4.57
1.55%-
1D1W1MYTD1YMAX
About scPharmaceuticals
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Ticker
SCPH
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
John Tucker
Employees
135
Headquarters
Burlington, United States
Website
www.scpharmaceuticals.com
SCPH Metrics
BasicAdvanced
$157M
Market cap
-
P/E ratio
-$1.42
EPS
0.09
Beta
-
Dividend rate
Price and volume
Market cap
$157M
Beta
0.09265
52-week high
$12.29
52-week low
$4.25
Average daily volume
204K
Financial strength
Current ratio
7.076
Quick ratio
6.403
Long term debt to equity
104.28
Total debt to equity
104.28
Interest coverage (TTM)
-18.35%
Management effectiveness
Return on assets (TTM)
-50.13%
Return on equity (TTM)
-99.97%
Return on investment (TTM)
-55.33%
Valuation
Price to revenue (TTM)
11.538
Price to book
4.204
Price to tangible book (TTM)
4.214
Growth
Earnings per share change (TTM)
-9.11%
What the Analysts think about SCPH
Analyst Ratings
Majority rating from 6 analysts.
Price Targets
Average projection from 6 analysts.
High $25.00
Low $16.00
$4.57
Current price
$19.50
Average price target
SCPH Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$6M
62.16%
Net income
-$14M
-11.54%
Profit margin
-230%
-45.45%
SCPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.41
-$0.35
-$0.36
-
Expected
-$0.37
-$0.36
-$0.42
-$0.44
-$0.40
Surprise
-3.33%
12.38%
-16.43%
-17.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for scPharmaceuticals stock?
scPharmaceuticals (SCPH) has a market cap of $157M as of May 15, 2024.
What is the P/E ratio for scPharmaceuticals stock?
The price to earnings (P/E) ratio for scPharmaceuticals (SCPH) stock is 0 as of May 15, 2024.
Does scPharmaceuticals stock pay dividends?
No, scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders as of May 15, 2024.
When is the next scPharmaceuticals dividend payment date?
scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders.
What is the beta indicator for scPharmaceuticals?
scPharmaceuticals (SCPH) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the scPharmaceuticals stock price target?
The target price for scPharmaceuticals (SCPH) stock is $19.5, which is 326.7% above the current price of $4.57. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell scPharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.